Benjamin Neale
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
There is still relatively little known about the genetic underpinnings of proteomic aging clocks. Here, we describe a genome-wide association study of proteomic aging in the UK Biobank (n=38,865), identifying 27 loci associated with participants’ proteomic age gap (ProtAgeGap). ProtAgeGap exhibits a strong genetic correlation with longevity (rg = −0.83), and in FinnGen a ProtAgeGap polygenic score (PGS) was associated with significantly increased odds of achieving longevity (n=500,348; OR = 1.43). Additional PGS analyses in All of Us (n=117,415), China Kadoorie Biobank (n=100,640), and ABCD Study (n=5,204) demonstrate reproducible associations across biobanks of ProtAgeGap PGS with obesity, cardiometabolic disease, and osteoarthritis in adults, and with developmental timing in children. Finally, colocalization analysis identified FTO as an obesity-related mechanism uniting diverse aging traits. Our results demonstrate a shared genetic architecture across the life course of ProtAgeGap with longevity, early developmental biology, and cardiometabolic and musculoskeletal diseases.
Year:
2025
One of the strongest signatures of aging is an accumulation of mutant mitochondrial DNA (mtDNA) heteroplasmy. Here we investigate the mechanism underlying this phenomenon by calling mtDNA sequence, abundance, and heteroplasmic variation in human blood using whole genome sequences from ∼750,000 individuals. Our analyses reveal a simple, two-step mechanism: first, individual cells randomly accumulate low levels of “cryptic” mtDNA mutations; then, when a cell clone proliferates, the cryptic mtDNA variants are carried as passenger mutations and become detectable in whole blood. Four lines of evidence support this model: (1) the mutational spectrum of age-accumulating mtDNA variants is consistent with a well-established model of mtDNA replication errors, (2) these mutations are found primarily at low levels of heteroplasmy and do not show evidence of positive selection, (3) high mtDNA mutation burden tends to co-occur in samples harboring somatic driver mutations for clonal hematopoiesis (CH), and (4) nuclear GWAS reveals that germline variants predisposing to CH (such as those near TERT , TCL1A , and SMC4 ) also increase mtDNA mutation burden. We propose that the high copy number and high mutation rate of mtDNA make it a particularly sensitive blood-based marker of CH. Importantly, our work helps to mechanistically unify three prominent signatures of aging: common germline variants in TERT , clonal hematopoiesis, and observed mtDNA mutation accrual.
Year:
2025
Key Points Question Is variation in global functioning among people with schizophrenia associated with genetic differences? Findings In this genetic association study of 5991 adults with schizophrenia and 59,795 hospitalizations, polygenic scores for schizophrenia and educational attainment predicted global functioning at psychiatric admission and discharge, as well as the magnitude of functional improvement during hospitalization. Higher polygenic burden for schizophrenia was consistently associated with worse functional outcomes, including less functional improvement during hospitalization, while educational attainment polygenic score showed a more complex pattern of associations. Meaning Polygenic scores may help disentangle heterogeneity in schizophrenia functioning and course. Importance Schizophrenia is characterized by heterogeneity in disease outcomes and course. The extent to which this heterogeneity is associated with genetic variation is unclear. Objective To investigate whether polygenic scores (PGS) for schizophrenia and educational attainment are associated with global functioning during inpatient psychiatric hospitalization among patients with schizophrenia. Design, Setting, and Participants Adults with schizophrenia were recruited nationwide for the SUPER-Finland Study between 2015 and 2018. Global functioning scores recorded during hospitalizations between 1994 and 2019 were extracted from a complete, longitudinal register. Data for the current genetic association study were analyzed between May 2024 and April 2025. We used linear mixed-effects models to examine associations among PGS and global functioning at admission and discharge, as well as functional change during hospitalization. Exposures Psychiatric hospitalization and PGS for schizophrenia and educational attainment. Main Outcomes and Measures Admission global functioning, discharge global functioning, and functional change during hospitalization. Results We analyzed 117,810 global functioning scores from 59,795 hospitalizations and 5991 participants (2733 [45.62%] female, median [IQR] age = 47 [20] years). Higher schizophrenia PGS predicted lower admission global functioning ( β = −0.20; 95% CI, −0.40 to 0.00; P = .05) and discharge global functioning ( β = −0.36; 95% CI,−0.56 to −0.17; P < .001), and less functional improvement ( β = −0.31; 95% CI, −0.49 to −0.14; P < .001). Higher educational attainment PGS predicted greater functional improvement ( β = 0.20; 95% CI, 0.03 to 0.37; P = .02) but worse admission global functioning ( β = −0.23; 95% CI, −0.43 to −0.04; P = .02). Conclusions and Relevance Higher genetic liability for schizophrenia is associated with worse global functioning across psychiatric hospitalization, including less functional improvement. Integrating PGS and clinically relevant, longitudinal disease outcomes may help parse heterogeneity in schizophrenia prognosis and course.
Year:
2025
Thyroid diseases are common and highly heritable. Under the Global Biobank Meta-analysis Initiative, we performed a meta-analysis of genome-wide association studies from 19 biobanks for five thyroid diseases: thyroid cancer, benign nodular goiter, Graves’ disease, lymphocytic thyroiditis, and primary hypothyroidism. We analyzed genetic association data from ∼2.9 million genomes and identified 235 known and 501 novel independent variants significantly linked to thyroid diseases. We discovered genetic correlations between thyroid cancer, benign nodular goiter, and autoimmune thyroid diseases ( r 2 =0.21-0.97). Telomere maintenance genes contribute to benign and malignant thyroid nodular disease risk, whereas cell cycle, DNA repair, and DNA damage response genes are predominantly associated with thyroid cancer. We proposed a paradigm explaining genetic predisposition to benign and malignant thyroid nodules. We evaluated thyroid cancer polygenic risk scores (PRS) for clinical applications in thyroid cancer diagnosis. We found PRS associations with thyroid cancer risk features: multifocality, lymph node metastases, and extranodal extension.
Year:
2025
Psychiatric disorders display high levels of comorbidity and genetic overlap 1,2 . Genomic methods have shown that even for schizophrenia and bipolar disorder, two disorders long-thought to be etiologically distinct 3 , the majority of genetic signal is shared 4 . Furthermore, recent cross-disorder analyses have uncovered over a hundred pleiotropic loci shared across eight disorders 5 . However, the full scope of shared and disorder-specific genetic basis of psychopathology remains largely uncharted. Here, we address this gap by triangulating across a suite of cutting-edge statistical genetic and functional genomic analyses applied to 14 childhood- and adult-onset psychiatric disorders (1,056,201 cases). Our analyses identify and characterize five underlying genomic factors 6 that explain the majority of the genetic variance of the individual disorders (∼66% on average) and are associated with 268 pleiotropic loci. We observed particularly high levels of polygenic overlap 7 and local genetic correlation 8 and very few disorder-specific loci 9 for two factors defined by: ( i ) schizophrenia and bipolar disorder (“SB factor”), and by ( ii ) major depression, PTSD, and anxiety (“internalizing factor”). At the functional level, we applied multiple methods 10–12 which demonstrated that the shared genetic signal across the SB factor was substantially enriched in genes expressed in excitatory neurons, whereas the internalizing factor was associated with oligodendrocyte biology. By comparison, the genetic signal shared across all 14 disorders was enriched for broad biological processes (e.g., transcriptional regulation). These results indicate increasing differentiation of biological function at different levels of shared cross-disorder risk, from quite general vulnerability to more specific pathways associated with subsets of disorders. These observations may inform a more neurobiologically valid psychiatric nosology and implicate novel targets for therapeutic developments designed to treat commonly occurring comorbid presentations.
Year:
2025
Motivation The Variant Call Format (VCF) is widely used in genome sequencing but scales poorly. For instance, we estimate a 150 000 genome VCF would occupy 900 TiB, making it costly and complicated to produce, analyze, and store. The issue stems from VCF’s requirement to densely represent both reference-genotypes and allele-indexed arrays. These requirements lead to unnecessary data duplication and, ultimately, very large files. Results To address these challenges, we introduce the Scalable Variant Call Representation (SVCR). This representation reduces file sizes by ensuring they scale linearly with samples. SVCR’s linear scaling relies on two techniques, both necessary for linearity: local allele indices and reference blocks, which were first introduced by the Genomic Variant Call Format. SVCR is also lossless and mergeable, allowing for N + 1 and N + K incremental joint-calling. We present two implementations of SVCR: SVCR-VCF, which encodes SVCR in VCF format, and VDS, which uses Hail’s native format. Our experiments confirm the linear scalability of SVCR-VCF and VDS, in contrast to the super-linear growth seen with standard VCF files. We also discuss the VDS Combiner, a scalable, open-source tool for producing a VDS from GVCFs and unique features of VDS which enable rapid data analysis. SVCR, and VDS in particular, ensure the scientific community can generate, analyze, and disseminate genetics datasets with millions of samples. Availability and implementation https://github.com/hail-is/hail/.
Year:
2024
Background The Populations Underrepresented in Mental illness Association Studies (PUMAS) project is attempting to remediate the historical underrepresentation of African and Latin American populations in psychiatric genetics through large-scale genetic association studies of individuals diagnosed with a serious mental illness [SMI, including schizophrenia (SCZ), schizoaffective disorder (SZA) bipolar disorder (BP), and severe major depressive disorder (MDD)] and matched controls. Given growing evidence indicating substantial symptomatic and genetic overlap between these diagnoses, we sought to enable transdiagnostic genetic analyses of PUMAS data by conducting phenotype alignment and harmonization for 89,320 participants (48,165 cases and 41,155 controls) from four cohorts, each of which used different ascertainment and assessment methods: PAISA n=9,105; PUMAS-LATAM n=14,638; NGAP n=42,953 and GPC n=22,624. As we describe here, these efforts have yielded harmonized datasets enabling us to analyze PUMAS genetic variation data at three levels: SMI overall, diagnoses, and individual symptoms. Methods In aligning item-level phenotypes obtained from 14 different clinical instruments, we incorporated content, branching nature, and time frame for each phenotype; standardized diagnoses; and selected 19 core SMI item-level phenotypes for analyses. The harmonization was evaluated in PUMAS cases using multiple correspondence analysis (MCA), co-occurrence analyses, and item-level endorsement. Outcomes We mapped >6,895 item-level phenotypes in the aggregated PUMAS data, in which SCZ (44.97%) and severe BP (BP-I, 31.53%) were the most common diagnoses. Twelve of the 19 core item-level phenotypes occurred at frequencies of > 10% across all diagnoses, indicating their potential utility for transdiagnostic genetic analyses. MCA of the 14 phenotypes that were present for all cohorts revealed consistency across cohorts, and placed MDD and SCZ into separate clusters, while other diagnoses showed no significant phenotypic clustering. Interpretation Our alignment strategy effectively aggregated extensive phenotypic data obtained using diverse assessment tools. The MCA yielded dimensional scores which we will use for genetic analyses along with the item level phenotypes. After successful harmonization, residual phenotypic heterogeneity between cohorts reflects differences in branching structure of diagnostic instruments, recruitment strategies, and symptom interpretation (due to cultural variation).
Year:
2024
Genome-wide association studies (GWAS) and rare-variant association studies (RVAS) have identified thousands of genes and variants associated with diverse human phenotypes, and have revealed pervasive pleiotropy among common variants; however, the extent of pleiotropy among rare variants remains incompletely characterized. Using rare variant association results from the UK Biobank (UKB), we systematically quantify gene-level pleiotropy across hundreds of phenotypes spanning multiple phenotypic domains and identify genes exhibiting allelic series. We develop ALLSPICE (ALLelic Spectrum of Pleiotropy Informed Correlated Effects), a statistical test for assessing variant effect heterogeneity within pleiotropic genes across quantitative traits. In ALB , a gene associated with both albumin and calcium levels, ALLSPICE reveals a subset of missense variants with heterogeneous effects across these traits. Protein structure-based analyses further demonstrate that missense variants associated with calcium levels but not albumin, as well as variants with opposing effects on the two traits, are enriched near known calcium-binding sites in the ALB protein. In this way, we present a systematic view of gene-level pleiotropy and effect heterogeneity among rare variants, illustrating how shared and trait-specific genetic effects can arise within the same gene. Our analysis provides a general approach for dissecting pleiotropic architecture and detecting rare variants with heterogeneous effects for downstream biological investigation of complex human traits.
Year:
2024
Motivation Functional Annotation of genomic Variants Online Resources (FAVOR) offers multi-faceted, whole genome variant functional annotations, which is essential for Whole Genome and Exome Sequencing (WGS/WES) analysis and the functional prioritization of disease-associated variants. A versatile chatbot designed to facilitate informative interpretation and interactive, user-centric summary of the whole genome variant functional annotation data in the FAVOR database is needed. Results We have developed FAVOR-GPT, a generative natural language interface powered by integrating large language models (LLMs) and FAVOR. It is developed based on the Retrieval Augmented Generation (RAG) approach, and complements the original FAVOR portal, enhancing usability for users, especially those without specialized expertise. FAVOR-GPT simplifies raw annotations by providing interpretable explanations and result summaries in response to the user’s prompt. It shows high accuracy when cross-referencing with the FAVOR database, underscoring the robustness of the retrieval framework. Availability and implementation Researchers can access FAVOR-GPT at FAVOR’s main website (https://favor.genohub.org).
Year:
2024
We deployed the Blended Genome Exome (BGE), a DNA library blending approach that generates low pass whole genome (1-4x mean depth) and deep whole exome (30-40x mean depth) data in a single sequencing run. This technology is cost-effective, empowers most genomic discoveries possible with deep whole genome sequencing, and provides an unbiased method to capture the diversity of common SNP variation across the globe. To evaluate this new technology at scale, we applied BGE to sequence >53,000 samples from the Populations Underrepresented in Mental Illness Associations Studies (PUMAS) Project, which included participants across African, African American, and Latin American populations. We evaluated the accuracy of BGE imputed genotypes against raw genotype calls from the Illumina Global Screening Array. All PUMAS cohorts had R 2 concordance ≥95% among SNPs with MAF≥1%, and never fell below ≥90% R 2 for SNPs with MAF<1%. Furthermore, concordance rates among local ancestries within two recently admixed cohorts were consistent among SNPs with MAF≥1%, with only minor deviations in SNPs with MAF<1%. We also benchmarked the discovery capacity of BGE to access protein-coding copy number variants (CNVs) against deep whole genome data, finding that deletions and duplications spanning at least 3 exons had a positive predicted value of ∼90%. Our results demonstrate BGE scalability and efficacy in capturing SNPs, indels, and CNVs in the human genome at 28% of the cost of deep whole-genome sequencing. BGE is poised to enhance access to genomic testing and empower genomic discoveries, particularly in underrepresented populations.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (77)
Jordan Smoller
Professor
Massachusetts General Hospital
M. Austin Argentieri
Broad Institute
Naomi Wray
University of Queensland
Vamsi Mootha
Investigator / Professor
-
Elinor Karlsson
Associate Professor
University of Massachusetts Chan Medical School
Serghei Mangul
University of Southern California
David van Heel
Professor
Queen Mary University of London
Stephen V Faraone
Distinguished Professor
SUNY Upstate Medical University
G. Bragi Walters
Research Assistant Professor
University of Iceland
Howard Edenberg
Distinguished Professor
Indiana University School of Medicine
Susan Santangelo
Research Professor
Tufts University School of Medicine
Ditte Demontis
Aarhus University
Robin Walters
University of Oxford
Na Cai
Assistant Professor
ETH Zürich
Alicia Martin
Assistant Professor
Massachusetts General Hospital
Michele Pato
Associate Dean for Academic Scholarship; Associate Chair for Education and Faculty Development; Della Martin Chair, Professor of Psychiatry; Clinical Director of Center for Genomic Psychiatry
Rutgers University
Bjørn Olav Åsvold
-
Joseph Powell
University of New South Wales
Roel A. Ophoff
Professor
University of California, Los Angeles
Shawneequa Callier
Associate Professor
George Washington University
Charles Newton
University of Oxford
Caroline Nievergelt
Professor
University of California, San Diego
James Knowles
Distinguished Professor and Executive Director of the HGINJ
Rutgers University - Busch Campus
Joanna Biernacka
Associate Professor
Mayo Clinic
Andrew Grotzinger
Associate Professor
Memorial University of Newfoundland
Lori Chibnik
Massachusetts General Hospital
Bizu Gelaye
Chief, Epidemiology Branch and Senior Investigator
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Kenneth S. Kendler
Professor
Virginia Commonwealth University
Pradeep Natarajan
Associate Professor
Harvard Medical School
John Hettema
Professor
Texas A&M University
Phil Lee
Associate Professor
Massachusetts General Hospital
Oleksandr Frei
Associate Professor (20%)
University of Oslo
Tim B. Bigdeli
SUNY Downstate Health Sciences University
Sandra Sanchez-Roige
Associate Professor
University of California, San Diego
Neil Wright
University of Oxford
Baihan Wang
University of Oxford
Toni Boltz
Massachusetts General Hospital
Evan Koch
Assistant Professor
Yale University
Aarno Palotie
University of Helsinki
Murray Stein
Distinguished Professor
University of California, San Diego
Canqing Yu
Associate Professor
Peking University
Derrick Bennett
Professor
University of Oxford
Zhiping Weng
Department Chair/Professor
University of Massachusetts Chan Medical School
Laura Thornton
Research Professor
University of North Carolina
Kari Stefansson
Professor
University of Iceland
Sarah Medland
QIMR Berghofer Medical Research Institute
Luke O'Connor
Assistant Professor
Harvard Medical School
David Whiteman
Deputy Director
QIMR Berghofer Medical Research Institute
Elizabeth Atkinson
Assistant Professor
Baylor College of Medicine
Najaf Amin
Associate Professor
University of Oxford
Joel Gelernter
Professor
Yale University School of Medicine
Markku Lähteenvuo
Niuvanniemi Hospital
Simone Rubinacci
FIMM/EMBL Group Leader in Statistical Genomics
University of Helsinki
Predrag Radivojac
Northeastern University
Zhengming Chen
Professor of Epidemeology, Director of China Programme
University of Oxford
Manuel Mattheisen
Associate Professor
Ludwig-Maximilians-Universität München
Barbara Franke
Head of department
Radboud University Medical Center
Michael Gandal
William & Noreen Hetznecker Associate Professor
University of Pennsylvania
Evan Giangrande
Assistant Professor
University of South Carolina
Josefin Werme
University of Amsterdam
Olli Pietilainen
Group Leader
University of Helsinki
Michael Talkowski
Professor
Massachusetts General Hospital
Karen Mitchell
Assistant Professor
Boston University
Shamil Sunyaev
Professor
Harvard University
Elliot M. Tucker-Drob
Faculty Research Associate
University of Texas at Austin
Dan Stein
Professor and Chair of Psychiatry
University of Cape Town
Ole A. Andreassen
Oslo University Hospital
Kai Yuan
Assistant Professor
Indiana University School of Medicine
Irwin Waldman
Professor
Emory University
Brandon Coombes
Assistant Professor of Biostatistics
Mayo Clinic
Wouter Peyrot
VU medisch centrum
Katherine Jonas
Assistant Professor
Stony Brook University
Cornelia Van Duijn
Professor
University of Oxford
Xihong Lin
Professor
Harvard University
Anne O'Donnell-Luria
Associate Professor
Boston Children's Hospital
Jaana Suvisaari
Research Professor
National Institute for Health and Welfare
John Nurnberger
Professor/Distinguished Professor
Indiana University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.